Study to Determine the Safety and Pharmacokinetics of DO-2 in Patients With Advanced or Refractory Solid Tumours

• Sponsor: DeuterOncology (Industry)
• Overall Status: Recruiting
• CT.gov ID: NCT05752552
• Collaborator: (none)
• Enrollment: 25
• Locations: 3
• Arms: 7
• Anticipated Duration (Months): 17.4
• Patients Per Site: 8.3
• Patients Per Site Per Month: 0.5

Study Details

Study Description

Brief Summary

This study is a first-in-human, open-label, 2-part, Phase 1 dose escalation study of DO-2, administered orally to patients with advanced or refractory solid tumours, with MET aberrations, and no available, approved therapeutic alternative.

Condition or Disease	Intervention/Treatment	Phase
Adult Solid Tumor; Advanced Solid Tumor; Refractory Tumor	Drug: DO-2	Phase 1

Detailed Description

In Part 1, a Simon Design 3 accelerated titration design will be followed. One patient will be enrolled per cohort, until grade 2 toxicity is observed. Three sequential patients per cohort will be enrolled thereafter, with a minimum of 1 week between first dose administration in the first patient and the subsequent ones, in those latter cohorts.

Study Design

• Study Type: Interventional
• Anticipated Enrollment: 25 participants
• Allocation: Non-Randomized
• Intervention Model: Sequential Assignment
• Masking: None (Open Label)
• Primary Purpose: Treatment
• Official Title: A Phase 1 Study to Determine the Safety, and Pharmacokinetics of the Selective MET Kinase Inhibitor, DO-2 in Patients With Advanced or Refractory Solid Tumours
• Actual Study Start Date: Dec 20, 2022
• Anticipated Primary Completion Date: Apr 1, 2024
• Anticipated Study Completion Date: Jun 1, 2024

Arms and Interventions

Arm	Intervention/Treatment
Experimental: Cohort 1 (starting dose) Oral administration, once a day for 28 days, in a 4-week cycle	Drug: DO-2; Deuterated MET kinase inhibitor
Experimental: Cohort 2 (dose level 2) Oral administration, once a day for 28 days, in a 4-week cycle	Drug: DO-2; Deuterated MET kinase inhibitor
Experimental: Cohort 3 (dose level 3) Oral administration, once a day for 28 days, in a 4-week cycle	Drug: DO-2; Deuterated MET kinase inhibitor
Experimental: Cohort 4 (dose level 4) Oral administration, once a day for 28 days, in a 4-week cycle	Drug: DO-2; Deuterated MET kinase inhibitor
Experimental: Cohort 5 (dose level 5) Oral administration, once a day for 28 days, in a 4-week cycle	Drug: DO-2; Deuterated MET kinase inhibitor
Experimental: Cohort 6 (dose level 6) Oral administration, once a day for 28 days, in a 4-week cycle	Drug: DO-2; Deuterated MET kinase inhibitor
Experimental: Cohort 7 (dose level 7) Oral administration, once a day for 28 days, in a 4-week cycle	Drug: DO-2; Deuterated MET kinase inhibitor

Outcome Measures

Primary Outcome Measures

1. Number of subjects who experience Dose Limiting Toxicities (DLTs) [Baseline up to Week 4]

   Only toxicities that occur during Cycle 1 will be considered for the purposes of defining DLT and for dose escalation, but toxicities that occur in all cycles will be recorded and considered in decisions about the Maximum Tolerated Dose. DLTs are defined as toxicities that meet pre-defined severity criteria. Toxicity grading will be performed in accordance with NCI-CTC Version 5.0.

2. Number of subjects who experience specific treatment-emergent adverse events (TEAEs) [Baseline up to Week 20]

   Number of subjects with specific treatment-emergent adverse events for each dose group. AE refers to any untoward medical occurrence or deterioration of existing medical event after the subject signed the ICF, whether or not considered related to the study treatment. TEAEs are any event that occurs after the subject has received study treatment. AE grading will be performed in accordance with NCI-CTC Version 5.0.

3. Number of subjects who discontinue DO-2 treatment due to adverse event [Baseline up to Week 20]

   Number of subjects who discontinue DO-2 treatment because of an adverse event for each dose group. AE grading will be performed in accordance with NCI-CTC Version 5.0.

4. Determination of the Maximum Tolerated Dose (MTD) [Baseline up to Week 20]

   The MTD in milligram is defined as the highest dose at which less than one third of the subjects in a dose level cohort experience DLT.

Secondary Outcome Measures

1. Maximum observed concentration (Cmax) of DO-2 [Baseline up to Day 23]

   Determine the Cmax of DO-2 and its primary metabolite in plasma sampled at different timepoints during Cycle 1.

2. Objective response rate (ORR) [Baseline through study completion, an average of 1 year]

   ORR is defined as the proportion of subjects with confirmed CR or confirmed PR. Radiologic assessment will be repeated after every second cycle (or more frequently if clinically indicated) and using same methodology as at baseline. Response assessment (radiologic) will be determined in accordance with RECIST (version 1.1) and current disease specific solid tumour response criteria.

3. Duration of response (DoR) [Baseline through study completion, an average of 1 year]

   DoR is defined as the duration from the first documentation of objective response to the first documented disease progression (based on RECIST Version 1.1) or death due to any cause, whichever occurs first.

4. Time to response (TTR) [Baseline through study completion, an average of 1 year]

   TTR is defined as the time from the start of the treatment to the first objective tumor response observed for patients who achieved CR or PR (based on RECIST Version 1.1).

5. Progression-free survival (PFS) [Baseline through study completion, an average of 1 year]

   PFS is defined as the time from the start of treatment until the first documentation of disease progression or death due to any cause, whichever occurs first (based on RECIST Version 1.1).

6. Overall survival (OS) [Baseline through study completion, an average of 1 year]

   OS defined as the time from the first dose to death from any cause.

Eligibility Criteria

Criteria

• Ages Eligible for Study: 18 Years and Older
• Sexes Eligible for Study: All
• Accepts Healthy Volunteers: No

Inclusion Criteria:

• 18 years or older

• histologically or cytologically confirmed advanced or refractory solid tumour and no longer eligible for approved, available standard therapies. Tumour types must have:

1. proven MET activating mutations, determined by previous next generation sequencing (NGS), whole exome sequencing (WES), whole transcriptome sequencing (WTS) or other genomic analysis methods, or

2. proven amplification (≥ 10 copies) on archived tumour tissue. or

3. Hereditary Renal Papillary Cancer

• Eastern Cooperative Oncology Group (ECOG) performance status ≤ 2

• adequate bone marrow function, without the support of cytokines

• adequate liver function

• adequate renal function

• agree to follow the contraception requirements of the trial

• signed informed consent, indicating study patients understand the purpose of and procedures required for the study and are willing to participate in the study.

Exclusion Criteria:

• major surgery within 3 weeks before enrollment

• chemotherapy (in the case of nitrosoureas and mitomycin C within 6 weeks), radiotherapy, immunotherapy, or any other study drug within 3 weeks before study drug administration

• antibody based cancer therapy within 4 weeks before administration of the first dose of DO-2

• patients with brain metastases are excluded unless all of the following criteria are met:

1. CNS lesions are asymptomatic and previously treated

2. No ongoing requirement for corticosteroids as therapy for CNS metastases

3. Imaging demonstrates stability of disease > 28 days from last treatment for CNS metastases

• leptomeningeal involvement (leptomeningeal carcinomatosis)

• history of uncontrolled heart disease including unstable angina, congestive heart failure, myocardial infarction within preceding 12 months, clinically significant rhythm or conduction abnormality, congenital long QT syndrome, obligate use of a cardiac pacemaker, QTc at screening greater than 450 milliseconds in males and greater than 470 milliseconds in females

• uncontrolled arterial hypertension despite appropriate therapy

• positive pregnancy test (urinary beta-hCG) at screening (applicable to women of child-bearing potential who are sexually active)

• mental status alteration or history of major psychiatric illness, which may potentially impair patient's compliance with study procedures

• signs and symptoms of active infection requiring systemic therapy

• other medical condition (e.g. pre-existing kidney dysfunction) that in the opinion of the investigator makes it undesirable for a patient to participate

Contacts and Locations

Locations

	Site	City	State	Country	Postal Code
1	Institut Roi Albert II - UC Louvain	Bruxelles		Belgium
2	UZA	Edegem		Belgium
3	Erasmus Medical Centre	Rotterdam		Netherlands

Sponsors and Collaborators

• DeuterOncology

Investigators

• Study Chair: Jaap Verweij, MD, CMO DeuterOncology

Study Documents (Full-Text)

None provided.

More Information

Additional Information:

• DeuterOncology Internet site

Publications

None provided.

• Responsible Party: DeuterOncology
• ClinicalTrials.gov Identifier: NCT05752552
• Other Study ID Numbers: DO2.22.01
• First Posted: Mar 2, 2023
• Last Update Posted: Mar 2, 2023
• Last Verified: Mar 1, 2023

• Individual Participant Data (IPD) Sharing Statement: No
• Plan to Share IPD: No
• Studies a U.S. FDA-regulated Drug Product: No
• Studies a U.S. FDA-regulated Device Product: No
• Additional relevant MeSH terms: Neoplasms

Study Results

No Results Posted as of Mar 2, 2023